^
    11ms
    AMpLify: CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=70, Recruiting, Caribou Biosciences, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV • CB-012
    11ms
    AMpLify: CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, Caribou Biosciences, Inc.
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV • CB-012
    12ms
    CLL-1-Targeted Allogeneic CAR-T Cells Exhibit High on-Target Specificity and Potent Cytotoxicity in Preclinical Models of Acute Myeloid Leukemia (ASH 2023)
    CB-012 demonstrated highly specific and potent CLL-1-targeted cytolytic activity in vitro and in vivo. Specificity of the anti-CLL-1 scFv was further demonstrated by screening in an unbiased protein-binding study and no adverse safety signals were observed in murine models. These data support advancing the development of CB-012 into a first-in-human clinical trial for patients with r/r AML.
    Preclinical • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • B2M (Beta-2-microglobulin) • HLA-E (Major Histocompatibility Complex, Class I, E)
    |
    PD-L1 expression • B2M elevation • B2M-HLA-E fusion
    |
    CB-012
    1year
    AMpLify: CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, Caribou Biosciences, Inc.
    New P1 trial • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV • CB-012
    over1year
    CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy engineered with next-generation CRISPR technology to resist both the immunosuppressive tumor microenvironment and immune cell-mediated rejection, for patients with relapsed or refractory acute myeloid leukemia (AACR 2023)
    CLL-1 is a compelling therapeutic target as it is highly expressed on AML tumor cells and leukemic stem cells, but not expressed on hematopoietic stem cells. It has also been established as a target in human proof-of-concept studies. CB-012 demonstrated potent and specific CLL-1-targeted cytolytic activity, and the genome-editing strategy employed to manufacture and armor CB-012 conferred a functional advantage in the context of the potentially immunosuppressive tumor microenvironment associated with r/r AML.
    Clinical • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker • Immune cell
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • B2M (Beta-2-microglobulin) • HLA-E (Major Histocompatibility Complex, Class I, E)
    |
    PD-L1 expression • B2M elevation • B2M-HLA-E fusion
    |
    CB-012